12/19
09:17 am
atyr
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% [Yahoo! Finance]
Low
Report
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% [Yahoo! Finance]
12/17
08:00 am
atyr
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/12
04:00 pm
atyr
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
Low
Report
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
12/10
12:21 pm
atyr
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
12/10
08:14 am
atyr
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis [Yahoo! Finance]
Medium
Report
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis [Yahoo! Finance]
12/10
08:00 am
atyr
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Medium
Report
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
12/9
08:15 am
atyr
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis [Yahoo! Finance]
Medium
Report
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis [Yahoo! Finance]
12/9
08:00 am
atyr
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
Medium
Report
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
12/3
12:19 pm
atyr
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
11/16
01:50 am
atyr
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
Medium
Report
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
11/15
08:05 am
atyr
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis [Yahoo! Finance]
Low
Report
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis [Yahoo! Finance]
11/15
08:00 am
atyr
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
Medium
Report
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
11/7
04:01 pm
atyr
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
Low
Report
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
10/31
03:32 pm
atyr
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA [Yahoo! Finance]
Low
Report
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA [Yahoo! Finance]
10/31
08:00 am
atyr
aTyr Pharma to Present at Upcoming Investor Conferences
Medium
Report
aTyr Pharma to Present at Upcoming Investor Conferences
10/29
08:00 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
10/8
08:00 am
atyr
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
Low
Report
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
10/4
07:36 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $17.00 price target on the stock.